Bizily Scott's most recent trade in 4D Molecular Therapeutics Inc was a trade of 584 Common Stock done at an average price of $6.5 . Disclosure was reported to the exchange on Sept. 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 01 Sep 2026 | 584 | 9,201 | - | 6.5 | 3,790 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2026 | 584 | 2,959 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 01 Sep 2026 | 584 | 8,617 | - | 14 | 8,176 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.14 per share. | 13 Aug 2026 | 1,635 | 10,252 | - | 4.1 | 6,769 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2026 | 1,635 | 59,701 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2026 | 1,635 | 61,336 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 12.20 per share. | 13 Aug 2026 | 1,635 | 8,617 | - | 12.2 | 19,947 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.14 per share. | 13 Aug 2026 | 1,635 | 10,252 | - | 4.1 | 6,769 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 13 Aug 2026 | 1,635 | 8,617 | - | 12 | 19,620 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 30 Jun 2026 | 6,566 | 8,617 | - | 14 | 91,924 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2026 | 5,752 | 3,543 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 30 Jun 2026 | 5,752 | 15,183 | - | 6.5 | 37,330 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.14 per share. | 30 Jun 2026 | 814 | 9,431 | - | 4.1 | 3,370 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2026 | 814 | 62,971 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2026 | 9,810 | 63,785 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 23 Jun 2026 | 9,810 | 8,617 | - | 12 | 117,720 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.14 per share. | 23 Jun 2026 | 9,810 | 18,427 | - | 4.1 | 40,613 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2026 | 217,000 | 217,000 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.14 per share. | 16 Dec 2025 | 1,635 | 5,229 | - | 4.1 | 6,769 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 10.90 per share. | 16 Dec 2025 | 1,635 | 3,594 | - | 10.9 | 17,822 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2025 | 1,635 | 73,595 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 1,635 | 75,230 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 10.59 per share. | 17 Nov 2025 | 1,635 | 3,594 | - | 10.6 | 17,315 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.14 per share. | 17 Nov 2025 | 1,635 | 5,229 | - | 4.1 | 6,769 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 24 Oct 2025 | 2,678 | 3,594 | - | 12 | 32,136 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 24 Oct 2025 | 1,084 | 6,272 | - | 6.5 | 7,035 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Oct 2025 | 1,084 | 9,295 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2025 | 1,635 | 76,865 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 10.17 per share. | 16 Oct 2025 | 1,635 | 5,188 | - | 10.2 | 16,628 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.14 per share. | 16 Oct 2025 | 1,635 | 6,823 | - | 4.1 | 6,769 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 09 Oct 2025 | 2,408 | 5,188 | - | 10 | 24,080 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 8.00 per share. | 23 Sep 2025 | 2,407 | 7,596 | - | 8 | 19,256 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 78,500 | 78,500 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 500 | 10,379 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 16.33 per share. | 16 Sep 2024 | 500 | 6,781 | - | 16.3 | 8,165 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 16 Sep 2024 | 500 | 7,281 | - | 6.5 | 3,245 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 19 Aug 2024 | 500 | 7,281 | - | 6.5 | 3,245 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 19 Aug 2024 | 500 | 6,781 | - | 15 | 7,500 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 500 | 10,879 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 27.11 per share. | 16 Jul 2024 | 1,750 | 6,781 | - | 27.1 | 47,443 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 16 Jul 2024 | 1,250 | 8,531 | - | 8.0 | 10,050 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2024 | 1,250 | 32,502 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 16 Jul 2024 | 500 | 7,281 | - | 6.5 | 3,245 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2024 | 500 | 11,379 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 11 Jul 2024 | 1,996 | 6,781 | - | 25 | 49,900 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.78 per share. | 11 Jul 2024 | 1,996 | 8,777 | - | 15.8 | 31,497 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2024 | 1,996 | 23,004 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 21.36 per share. | 01 Jul 2024 | 4,248 | 1,737 | - | 21.4 | 90,758 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 01 Jul 2024 | 2,916 | 5,985 | - | 8.0 | 23,445 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 2,916 | 33,752 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 01 Jul 2024 | 1,332 | 3,069 | - | 6.5 | 8,645 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 1,332 | 11,879 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 23.71 per share. | 17 Jun 2024 | 1,750 | 1,737 | - | 23.7 | 41,494 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2024 | 1,250 | 36,668 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 17 Jun 2024 | 1,250 | 3,487 | - | 8.0 | 10,050 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 17 Jun 2024 | 500 | 2,237 | - | 6.5 | 3,245 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2024 | 500 | 13,211 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 25.34 per share. | 16 May 2024 | 1,283 | 2,204 | - | 25.3 | 32,514 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2024 | 1,250 | 37,918 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 16 May 2024 | 1,250 | 3,487 | - | 8.0 | 10,050 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 16 May 2024 | 500 | 2,237 | - | 6.5 | 3,245 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2024 | 500 | 13,711 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 25.75 per share. | 16 May 2024 | 467 | 1,737 | - | 25.8 | 12,027 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 25.74 per share. | 16 Apr 2024 | 1,750 | 1,737 | - | 25.7 | 45,045 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 16 Apr 2024 | 1,250 | 3,487 | - | 8.0 | 10,050 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2024 | 1,250 | 39,168 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 16 Apr 2024 | 500 | 2,237 | - | 6.5 | 3,245 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2024 | 500 | 14,211 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 31.78 per share. | 01 Apr 2024 | 8,153 | 1,737 | - | 31.8 | 259,102 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 2,916 | 40,418 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 01 Apr 2024 | 2,916 | 5,985 | - | 8.0 | 23,445 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 1,996 | 21,008 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.78 per share. | 01 Apr 2024 | 1,996 | 7,981 | - | 15.8 | 31,497 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 1,909 | 46,182 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.24 per share. | 01 Apr 2024 | 1,909 | 9,890 | - | 20.2 | 38,638 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 01 Apr 2024 | 1,332 | 3,069 | - | 6.5 | 8,645 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 1,332 | 14,711 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 35.04 per share. | 27 Mar 2024 | 5,833 | 1,737 | - | 35.0 | 204,410 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2024 | 4,342 | 55,658 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.98 per share. | 27 Mar 2024 | 4,342 | 6,079 | - | 26.0 | 112,805 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2024 | 1,491 | 54,167 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.98 per share. | 27 Mar 2024 | 1,491 | 7,570 | - | 26.0 | 38,736 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 31.27 per share. | 18 Mar 2024 | 1,750 | 1,737 | - | 31.3 | 54,723 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 18 Mar 2024 | 1,250 | 3,487 | - | 8.0 | 10,050 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2024 | 1,250 | 43,334 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2024 | 500 | 16,043 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 18 Mar 2024 | 500 | 2,237 | - | 6.5 | 3,245 | Common Stock |
| 4D Molecular Therapeutics Inc | Bizily Scott | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.24 per share. | 27 Feb 2024 | 1,909 | 3,646 | - | 20.2 | 38,638 | Common Stock |
| 4D Molecular Therapeutics Inc | Bizily Scott | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 27 Feb 2024 | 1,909 | 1,737 | - | 30 | 57,270 | Common Stock |
| 4D Molecular Therapeutics Inc | Bizily Scott | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2024 | 1,909 | 48,091 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 27.67 per share. | 16 Feb 2024 | 1,750 | 1,737 | - | 27.7 | 48,423 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 16 Feb 2024 | 1,250 | 3,487 | - | 8.0 | 10,050 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 1,250 | 44,584 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Bizily Scott | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 500 | 16,543 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 16 Feb 2024 | 500 | 2,237 | - | 6.5 | 3,245 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 2,916 | 45,834 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 08 Feb 2024 | 2,916 | 4,653 | - | 8.0 | 23,445 | Common Stock |
| 4D Molecular Therapeutics Inc | Bizily Scott | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 27.50 per share. | 08 Feb 2024 | 2,916 | 1,737 | - | 27.5 | 80,190 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.78 per share. | 08 Feb 2024 | 1,996 | 3,733 | - | 15.8 | 31,497 | Common Stock |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 1,996 | 23,004 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Scott Bizily | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 27.50 per share. | 08 Feb 2024 | 1,996 | 1,737 | - | 27.5 | 54,890 | Common Stock |